969 related articles for article (PubMed ID: 29859759)
21. [The level of soluble programmed death-1 in peripheral blood of patients with lung cancer and its clinical implications].
Xing YF; Zhang ZL; Shi MH; Ma Y; Chen YJ
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):102-6. PubMed ID: 22455965
[TBL] [Abstract][Full Text] [Related]
22. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
Cheng Y; Wang C; Wang Y; Dai L
Future Oncol; 2022 Jan; 18(2):261-273. PubMed ID: 34874185
[TBL] [Abstract][Full Text] [Related]
23. Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.
Fujimoto D; Sato Y; Morimoto T; Uehara K; Ito M; Otsuka K; Nagata K; Sakanoue I; Hamakawa H; Nakagawa A; Takahashi Y; Imai Y; Tomii K
Clin Lung Cancer; 2018 Sep; 19(5):e667-e673. PubMed ID: 29844002
[TBL] [Abstract][Full Text] [Related]
24. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer.
Zer A; Sung MR; Walia P; Khoja L; Maganti M; Labbe C; Shepherd FA; Bradbury PA; Feld R; Liu G; Iazzi M; Zawisza D; Nouriany N; Leighl NB
Clin Lung Cancer; 2018 Sep; 19(5):426-434.e1. PubMed ID: 29803574
[TBL] [Abstract][Full Text] [Related]
25. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
Sato M; Watanabe S; Tanaka H; Nozaki K; Arita M; Takahashi M; Shoji S; Ichikawa K; Kondo R; Aoki N; Hayashi M; Ohshima Y; Koya T; Ohashi R; Ajioka Y; Kikuchi T
PLoS One; 2019; 14(4):e0215292. PubMed ID: 30978241
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
[TBL] [Abstract][Full Text] [Related]
27. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Ready N; Hellmann MD; Awad MM; Otterson GA; Gutierrez M; Gainor JF; Borghaei H; Jolivet J; Horn L; Mates M; Brahmer J; Rabinowitz I; Reddy PS; Chesney J; Orcutt J; Spigel DR; Reck M; O'Byrne KJ; Paz-Ares L; Hu W; Zerba K; Li X; Lestini B; Geese WJ; Szustakowski JD; Green G; Chang H; Ramalingam SS
J Clin Oncol; 2019 Apr; 37(12):992-1000. PubMed ID: 30785829
[TBL] [Abstract][Full Text] [Related]
28. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
29. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer.
Inoue Y; Yoshimura K; Nishimoto K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Asada K; Uto T; Fujii M; Matsui T; Matsuura S; Hashimoto D; Toyoshima M; Kusagaya H; Matsuda H; Inami N; Kaida Y; Niwa M; Ito Y; Sugimura H; Suda T
JAMA Netw Open; 2020 Sep; 3(9):e2011818. PubMed ID: 32955570
[TBL] [Abstract][Full Text] [Related]
31. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
[TBL] [Abstract][Full Text] [Related]
32. Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.
Yang Q; Chen M; Gu J; Niu K; Zhao X; Zheng L; Xu Z; Yu Y; Li F; Meng L; Chen Z; Zhuo W; Zhang L; Sun J
Front Immunol; 2021; 12():665133. PubMed ID: 33936103
[TBL] [Abstract][Full Text] [Related]
33. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
34. Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.
Park W; Mezquita L; Okabe N; Chae YK; Kwon D; Saravia D; Auclin E; Planchard D; Caramella C; Ferrara R; Agte S; Oh M; Mudad R; Jahanzeb M; Suzuki H; Besse B; Lopes G
Br J Cancer; 2020 Feb; 122(3):340-347. PubMed ID: 31761899
[TBL] [Abstract][Full Text] [Related]
35. Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis.
Shimizu T; Inoue E; Ohkuma R; Kobayashi S; Tsunoda T; Wada S
Front Immunol; 2023; 14():1308381. PubMed ID: 38115995
[TBL] [Abstract][Full Text] [Related]
36. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
Wang H; Wang L; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Li ZM; Lu Y
Oncotarget; 2016 May; 7(22):33035-45. PubMed ID: 27105512
[TBL] [Abstract][Full Text] [Related]
37. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
Takeuchi M; Doi T; Obayashi K; Hirai A; Yoneda K; Tanaka F; Iwai Y
Immunol Lett; 2018 Apr; 196():155-160. PubMed ID: 29366663
[TBL] [Abstract][Full Text] [Related]
38. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
39. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
40. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer.
Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Mimae T; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
Int J Clin Oncol; 2020 Jan; 25(1):74-81. PubMed ID: 31531785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]